Literature DB >> 11150636

Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice.

V B Kumar1, S A Farr, J F Flood, V Kamlesh, M Franko, W A Banks, J E Morley.   

Abstract

beta amyloid protein (Abeta) is a 40-43 amino acid peptide derived from amyloid precursor protein (APP). Abeta has been implicated as a cause of Alzheimer's disease (AD). Mice with spontaneous or transgenic overexpression of APP show the histologic hallmarks of AD and have impairments in learning and memory. We tested whether antisense phosphorothiolated oligonucleotides (AO) directed at the Abeta region of the APP gene given with or without antibody directed at Abeta could reverse the elevated protein levels of APP and the behavioral impairments seen in SAMP8 mice, a strain which spontaneously overexpresses APP. We found that intracerebroventricular (ICV) administration of antibody with either of two AOs directed at the midregion of Abeta improved acquisition and retention in a footshock avoidance paradigm, whereas two AOs directed more toward the C-terminal, a random AO, and vehicle were without effect. Three injections of the more potent AO given without antibody reduced APP protein levels by 43-68% in the amygdala, septum, and hippocampus. These results show that AO directed at the Abeta region of APP can reduce APP levels in the brain and reverse deficits in learning and memory.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11150636     DOI: 10.1016/s0196-9781(00)00339-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  46 in total

1.  Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins.

Authors:  Naoko Nonaka; Susan A Farr; Tomoya Nakamachi; John E Morley; Masanori Nakamura; Seiji Shioda; William A Banks
Journal:  Peptides       Date:  2012-06-09       Impact factor: 3.750

2.  The history of the Department of Internal Medicine at Saint Louis University.

Authors:  Adrian M Di Bisceglie; Connie Manning; Assako Holyoke
Journal:  Mo Med       Date:  2012 Mar-Apr

3.  Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice.

Authors:  Karin E Sandoval; Susan A Farr; William A Banks; Michael L Niehoff; John E Morley; Albert M Crider; Ken A Witt
Journal:  Eur J Pharmacol       Date:  2010-12-24       Impact factor: 4.432

Review 4.  Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence.

Authors:  Koji Tomobe; Yasuyuki Nomura
Journal:  Neurochem Res       Date:  2009-02-27       Impact factor: 3.996

Review 5.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

6.  Microarray profile of brain aging-related genes in the frontal cortex of SAMP8.

Authors:  Shao-Chun Chen; Gang Lu; Chu-Yan Chan; Yangchao Chen; Hua Wang; David Tai-Wai Yew; Zhong-Tang Feng; Hsiang-Fu Kung
Journal:  J Mol Neurosci       Date:  2009-10-17       Impact factor: 3.444

7.  Editorial: can we improve care for patients with dementia?

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

Review 8.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

9.  Editorial: What is the Physiological Function of Amyloid-Beta Protein?

Authors:  J E Morley; S A Farr; A D Nguyen; F Xu
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

10.  Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice.

Authors:  Susan A Farr; Michelle A Erickson; Michael L Niehoff; William A Banks; John E Morley
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.